Cheng Han Ng
@ChengHanNg
Followers
1K
Following
22K
Media
239
Statuses
1K
Physician, Biotech & Researcher of Metabolic Diseases | RT =/ Support
Right Upper Quadrant
Joined January 2021
#LiverTwitter Grateful to be listed (again) in Stanford’s Top 2% Scientists this year 🧑🔬📊& 2nd year in a row 🙏 Big thanks to mentors, collaborators & colleagues who make the journey possible. Excited to keep learning & building 🚀✨
2
1
18
#LiverTwitter While I was unable to attend #TLM2025 , very happy to see my CORE (cirrhosis outcomes and research endeavour) continues its growth to 20 sites in 1 year! 😍 We have completed and submitted 3 manuscripts, collected over 4000 patients and working on another 5 papers!
0
1
16
#LiverTwitter While I was unable to attend #TLM2025 , very happy to see my CORE (cirrhosis outcomes and research endeavour) continues its growth to 20 sites in 1 year! 😍 We have completed and submitted 3 manuscripts, collected over 4000 patients and working on another 5 papers!
0
1
16
#LiverTwitter Excited to share our latest study in @AGA_CGH Using >44,000 SRTR waitlist registrants, we found that while MELD 3.0 reclassifies many MASH patients, it doesn’t translate into better transplant access despite higher predicted mortality risk. https://t.co/FQvW8lnhfH
2
4
17
#LiverTwitter Excited to share our latest study in @AGA_CGH Using >44,000 SRTR waitlist registrants, we found that while MELD 3.0 reclassifies many MASH patients, it doesn’t translate into better transplant access despite higher predicted mortality risk. https://t.co/FQvW8lnhfH
2
4
17
#LiverTwitter Our new study published in APT! where "Less than 10% of patients received the recommended biannual ultrasound scans for surveillance."😱 https://t.co/WhL5TDQq9j
@KarnJUVE @nogamia_liver @DrHuangDQ @DrMarkMuthiah @PojsakornDan
1
6
24
#LiverTwitter Our new study published in APT! where "Less than 10% of patients received the recommended biannual ultrasound scans for surveillance."😱 https://t.co/WhL5TDQq9j
@KarnJUVE @nogamia_liver @DrHuangDQ @DrMarkMuthiah @PojsakornDan
1
6
24
#LiverTwitter Grateful to be listed (again) in Stanford’s Top 2% Scientists this year 🧑🔬📊& 2nd year in a row 🙏 Big thanks to mentors, collaborators & colleagues who make the journey possible. Excited to keep learning & building 🚀✨
2
1
18
#LiverTwitter Read our new meta-analysis in CGH: Patients with MASLD + advanced fibrosis face a real risk of HCC, even without cirrhosis. 📈 Incidence climbs from ~0.8% at 1 yr → ~9% at 10 yrs. 🔗 https://t.co/CkBnITxvM2
0
4
13
#LiverTwitter Excited to share our new study in Scientific Reports! 🎉 We developed a simple formula using age, trunk fat & muscle mass (via BIA) to estimate liver steatosis in MASLD. 📈 eCAP performed well (AUROC ~0.80). 🔗 https://t.co/DpA1Sv8cvY
0
2
9
#LiverTwitter Excited to share our new study in Scientific Reports! 🎉 We developed a simple formula using age, trunk fat & muscle mass (via BIA) to estimate liver steatosis in MASLD. 📈 eCAP performed well (AUROC ~0.80). 🔗 https://t.co/DpA1Sv8cvY
0
2
9
#LiverTwitter Read our new meta-analysis in CGH: Patients with MASLD + advanced fibrosis face a real risk of HCC, even without cirrhosis. 📈 Incidence climbs from ~0.8% at 1 yr → ~9% at 10 yrs. 🔗 https://t.co/CkBnITxvM2
0
4
13
#ICOMES2025 was fabulous. Thankful to my friend, Dr Moon for inviting me to the faculty dinner with K-pop appearance! Legendary conference ❤️ Korea’s great food is contradictory to the conference topic though!
0
1
4
#ICOMES2025 was fabulous. Thankful to my friend, Dr Moon for inviting me to the faculty dinner with K-pop appearance! Legendary conference ❤️ Korea’s great food is contradictory to the conference topic though!
0
1
4
0
0
5
🌍 Our first online meeting for CORE (Cirrhosis Outcomes & Research Endeavors)! Founded by Myself, @DrMarkMuthiah and Hirokazu Takahashi, CORE united 11 sites (🇸🇬🇺🇸🇮🇳🇨🇳🇭🇰🇹🇭🇯🇵🇺🇸🇸🇬🇹🇭🇮🇳) to study compensated cirrhosis with 3500+ patients, with more joining soon from 🇺🇸🇰🇷🇦🇺🇬🇧 🇯🇵🇯🇵.
1
1
19
🌍 Our first online meeting for CORE (Cirrhosis Outcomes & Research Endeavors)! Founded by Myself, @DrMarkMuthiah and Hirokazu Takahashi, CORE united 11 sites (🇸🇬🇺🇸🇮🇳🇨🇳🇭🇰🇹🇭🇯🇵🇺🇸🇸🇬🇹🇭🇮🇳) to study compensated cirrhosis with 3500+ patients, with more joining soon from 🇺🇸🇰🇷🇦🇺🇬🇧 🇯🇵🇯🇵.
1
1
19
In this consortium study of academic centres in Singapore, Japan, Korea, and Australia @JAMANetworkOpen by @NUSMedicine student Ryan Lim, HCC surveillance was a/w ⬆️survival, but the benefit appeared less consistent in MASLD/ALD. @ChengHanNg @KarnJUVE
@AnandVKulkarni2
Surveillance improved survival rates in hepatocellular carcinoma (HCC) but was less consistent for metabolic and alcohol-associated HCC. https://t.co/pyio59vwvz
0
9
25
@ChengHanNg @JAMANetworkOpen We also found the same in our multi-centre UK study!! Aetiology clearly plays an important role. More research needed 🔍 https://t.co/MaO3J8jQkq
pubmed.ncbi.nlm.nih.gov
HCC surveillance as currently delivered was less effective for detecting early-stage HCC in patients with non-viral and non-cirrhotic liver disease. Gender and ethnicity influences stage at present...
0
2
2
Amazing
Just published Our international study of 1,185 patients in @JAMANetworkOpen shows that HCC surveillance is linked to better survival, especially in those with HBV- or HCV-related liver cancer. Less clear benefit in MASLD/alcohol-related HCC. Liver Etiology matters!
0
1
3